Navigation Links
Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Date:4/25/2012

VANCOUVER, British Columbia, April 25, 2012 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 Medical Device 360 Conference on Wednesday, April 25, 2012. The conference is being held at the Millennium Gloucester Hotel, London, UK.

The IN3 Medical Device 360 Conference is hosted by Elsevier and is a medical device industry forum and networking meeting. The goal of the meeting is 'partnering medtech innovators with top investors and corporate acquirers'. Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial.

"Hospital acquired infections remain a global problem. In the United States alone, these infections drain an estimated $30-45 billion dollars per year from the healthcare system. Enox's antimicrobial technology is uniquely positioned to address this problem by utilizing nitric oxide as the mechanism of action. Nitric oxide is an ideal antimicrobial agent as it is very effective but does not have resistance issues like antibiotics do."

"The IN3 Medical Device 360 Conference will provide great exposure to European market in terms of investors and potential strategic partners," continued Rewcastle. "Our breakthrough technology has the potential to meet the needs of hospitals worldwide who are currently underserved by existing infection prevention technologies."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to, catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone
888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com

 


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Equity Research on Most Popular Searches: Atmel, USG, Applied Materials, Sprint Nextel, Galena Biopharma, and Key Energy Services
2. Enox Biopharma, Inc. Will Be Granted its Foundation Patent
3. Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
4. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
5. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
6. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
7. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
8. Plato BioPharma, Inc Appoints New Board Member
9. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on ... presentation entitled "High doses of biotin in progressive multiple sclerosis: ... by Professor Ayman Tourbah , Principal Investigator of the ... Academy of Neurology (EAN) in Copenhagen, Denmark ... take place on Sunday, 29 May 2016 from 14:45 to ...
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager public ... unaware of the plight of aphasia. In collaboration with the American Aphasia Association, ... , The link between stroke and aphasia is relatively unknown, but through collaboration ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in the health ... of leaders in the nursing and health care industry. It also provides insight to ... Christian University. , As the nursing industry is coming out of one of ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... Despite last ... meeting, expect Janet Yellen and company to wait until March 2017 for an interest ... University’s J. Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, ... defective respirators, according to court documents and SEC filings. A jury has ... Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its ... partner for the Tamika Catchings Legacy Tour that will commemorate the Indiana ... hardwood basketball surfaces in all forms and levels of the game, Connor Sports has ...
Breaking Medicine News(10 mins):